MISSISSAUGA, ONTARIO--(Marketwire - February 05, 2008) - BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that it has signed an agreement with a pharmaceutical developer and manufacturer for the licensing and supply of a new pharmaceutical product. This new product will be marketed as a generic drug in Canada. The product launch is subject to regulatory approval.
